Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 20 November 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has issued a new warning that Lexiscan (regadenoson) and Adenoscan (adenosine), two intravenously-administered drugs used during cardiac nuclear stress tests, are associated with "rare but serious" side effects that can result in heart attack and death.
Cardiac nuclear stress tests are used to assess the body's capacity to circulate blood by capturing images of the heart during states of rest and physical activity. They are generally used in cases when a basic (i.e. exercise) stress test is not feasible or did not generate conclusive results.
Both Lexiscan and Adenoscan are used to dilate the arteries of the heart during the procedure, thereby allowing the scan to determine where blockages or obstructions exist in nearby arteries.
As explained by FDA in its 20 November 2013 announcement, the drugs already contained labeling indicating the risk of heart attack and death.
"However, recent reports of serious adverse events in the FDA Adverse Event Reporting System (FAERS) database and the medical literature prompted us to approve changes to the drug labels to include updated recommendations for use," FDA explained. "Some events occurred in patients with signs or symptoms of acute myocardial ischemia, such as unstable angina or cardiovascular instability," it added.
Regulators said they believed this occurs as a result of blood flowing disproportionately toward healthier or unobstructed arteries during the test, reducing the flow to other areas and causing a heart attack.
As a result, FDA said precautionary measures should be taken during all cardiac nuclear stress tests. For example, cardiac resuscitation equipment should be on hand along with staff trained in its use. These warnings will be reflected in newly updated labels for the drugs, FDA stated.
Both Adenoscan and Lexiscan are manufactured by Astellas.
FDA Announcement
Tags: Astellas
Regulatory Focus newsletters
All the biggest regulatory news and happenings.